Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € ↓ -1,30 (-0,35%)
2026-06-03
DEL PRIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionMan Group plc
Latest Disclosed Ownership236,798 shares
Latest Disclosed Value $ 105,739,779
Man Group plc ownership in 1VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 236,798 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $89,888,521 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 380,735 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -37.81% during the quarter. The current value of the position is $86,739,107 USD.

Man Group plc has a history of taking positions in derivatives of the underlying security (1VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 236,798 -143,937 -37.81 105,740 -38.74 0.1918
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 380,735 17,961 4.95 172,610 21.49 0.2934
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 362,774 235,156 184.27 142,077 150.07 0.2471
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 127,618 112,434 740.48 56,816 671.84 0.1082
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,184 -73,542 -82.89 7,362 -79.40 0.0187
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 88,726 37,008 71.56 35,730 48.54 0.0940
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 51,718 -145,578 -73.79 24,053 -73.99 0.0626
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 197,296 -330,628 -62.63 92,477 -58.09 0.2336
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 527,924 173,126 48.80 220,678 52.86 0.5564
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 354,798 144,364 52.15 0.4020
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 94,879 -29.57 0.2940
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 382,820 134,718 21.04 0.4156
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 111,303 -33.13 0.3959
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 576,398 340,716 144.57 166,452 143.92 0.5967
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 235,682 68,240 97.19 0.3167
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,607 -69.21 0.1467
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 430,760 -532,765 -55.29 112,415 -46.87 0.3911
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 963,525 -247,918 -20.46 211,590 -3.71 0.6803
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,211,443 371,319 44.20 219,744 29.72 0.7708
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 840,124 202,762 31.81 169,394 23.68 0.5964
2021-05-17 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 637,362 -290,549 -31.31 136,963 -37.55 0.6022
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 927,911 217,679 30.65 219,303 13.47 0.9628
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 710,232 117,797 19.88 193,269 12.37 0.7605
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 592,435 -75,565 -11.31 171,989 8.20 0.8673
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 668,000 431,635 182.61 158,950 207.14 1.0298
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 236,365 171,786 266.01 51,752 373.01 0.1702
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 64,579 -67,846 -51.23 10,941 -54.95 0.0406
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 132,425 25,460 23.80 24,284 23.42 0.0878
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 106,965 -123,977 -53.68 19,676 -48.59 0.0746
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 230,942 135,385 141.68 38,269 107.78 0.1703
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 95,557 -40,728 -29.88 18,418 -20.49 0.0673
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 136,285 23,668 21.02 23,163 26.20 0.0953
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 112,617 112,617 18,354 0.0840
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM Call 1,200 218 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM Put 1,200 218 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.